Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 21;31(3):99983.
doi: 10.3748/wjg.v31.i3.99983.

WNT/β-catenin-M2 macrophage interplay as a target for therapy against hepatocellular carcinoma: Role of Calculus bovis

Tryfonas Mpektsis  1 , Anastasios Manolakis  2 , Andreas Kapsoritakis  1
Affiliations

WNT/β-catenin-M2 macrophage interplay as a target for therapy against hepatocellular carcinoma: Role of Calculus bovis

Tryfonas Mpektsis et al. World J Gastroenterol. .

Abstract

Liver cancer, and in particular hepatocellular carcinoma (HCC) is a disease of rising prevalence and incidence. To date, definitive treatment options include either surgical excision or ablation of the affected area. With increasing research on several pathways that could be involved in the progression of HCC, new elements within these pathways emerge as potential targets for novel therapies. The WNT/β-catenin pathway favors the presence of M2 tumor-associated macrophages which in turn promote tumor growth and metastasis. The inhibition of this pathway is considered a good candidate for such targeted therapeutic interventions. Interestingly, as Huang et al show in their recently published article, Calculus bovis which is used in traditional Chinese medicine can exert an inhibitory effect on the β-catenin pathway and become a potential candidate for targeted pharmacotherapy against liver cancer.

Keywords: Calculus bovis; Hepatocellular carcinoma; Tumor-associated macrophages; WNT/β-catenin pathway.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors have nothing to disclose.

Similar articles

See all similar articles

References

    1. Nusse R, Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169:985–999. - PubMed
    1. Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu C, Wang C, Ye L. Wnt/β-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6:307. - PMC - PubMed
    1. Huang Z, Meng FY, Lu LZ, Guo QQ, Lv CJ, Tan NH, Deng Z, Chen JY, Zhang ZS, Zou B, Long HP, Zhou Q, Tian S, Mei S, Tian XF. Calculus bovis inhibits M2 tumor-associated macrophage polarization via Wnt/β-catenin pathway modulation to suppress liver cancer. World J Gastroenterol. 2024;30:3511–3533. - PMC - PubMed
    1. Cerreto M, Cardone F, Cerrito L, Stella L, Santopaolo F, Pallozzi M, Gasbarrini A, Ponziani FR. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence. Curr Oncol. 2023;30:8774–8792. - PMC - PubMed
    1. Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125–137. - PubMed

MeSH terms